{"commentary":{"count":17,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":9,"podcast":6,"x_thread":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06382948\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"ADELA","nct_id":"NCT06382948","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=adela-nct06382948. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"ADELA","arms":[{"description":"Patients will receive 345 mg of elacestrant and 7.5 mg of everolimus orally once daily.\n\nPatients will remain in treatment until disease progression, treatment discontinuation, the start of new anti-cancer treatment, withdrawal of consent, death, or EoS, whichever occurs first.","label":"Interventional Arm 1","type":"EXPERIMENTAL"},{"description":"Patients will receive elacestrant at (345 mg orally once daily) plus matched everolimus placebo.\n\nPatients will remain in treatment until disease progression, treatment discontinuation, the start of new anti-cancer treatment, withdrawal of consent, death, or EoS, whichever occurs first.","label":"Control Arm 2","type":"ACTIVE_COMPARATOR"}],"collaborators":["Stemline Therapeutics, Inc."],"completion_date":{"date":"2028-04","type":"ESTIMATED"},"conditions":["Advanced Breast Cancer","ER-positive Breast Cancer","HER2-negative Breast Cancer","ESR1 Gene Mutation"],"enrollment":{"count":300,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Everolimus","type":"DRUG"},{"name":"Elacestrant","type":"DRUG"},{"name":"Placebo","type":"DRUG"},{"name":"Auxiliary Medicinal Product - Dexamethasone","type":"DRUG"},{"name":"Auxiliary Medicinal Product - Luteinizing hormone-releasing hormone (LHRH) analogues","type":"DRUG"}],"last_update":"2026-08-24","lead_sponsor":"MedSIR","official_title":"A Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Elacestrant Plus Everolimus Versus Elacestrant in Patients With ER+/HER2-, ESR1mut Advanced Breast Cancer Progressing to Endocrine Therapy and CDK4/6 Inhibitors","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-09","type":"ESTIMATED"},"primary_outcomes":[{"measure":"To demonstrate superiority of elacestrant+everolimus vs. elacestrant+placebo in prolonging PFS based on a BIRC in patients with ER[+]/HER2[-], ESR1-mutated, ABC that have previously received ET+CDK4/6i (all patients).","timeFrame":"Until disease progression, treatment discontinuation, the start of new anti-cancer treatment, withdrawal of consent, death, or EoS, whichever occurs first, assessed through study completion, an average of 12 months."}],"references":[],"start_date":{"date":"2024-12-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.","url":"https://clinicaltrials.gov/study/NCT06382948"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/adela-nct06382948"}